Lupus nephritis in children ? a review of 167 patients

Yang, Lingwei; Chen, Wei Perng; Lin, Ching Yuang

doi:10.1007/bf00860937

Cited by 67 publications

(95 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although in the last decade, there has been a significant improvement in the morbidity and mortality of treated children with SLE, there remains a cohort of children who do not respond to conventional therapy with corticosteroids and cyclophosphamide and other immunosuppressive agents (28)(29)(30)(31)(32)(33). In addition, the side effects of cytotoxic immunotherapy (mainly relating to cyclophosphamide) are not inconsequential in children.…”

Section: Discussionmentioning

confidence: 99%

B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus

Marks¹,

Patey²,

Brogan³

et al. 2005

Arthritis & Rheumatism

143

View full text Add to dashboard Cite

Objective. To determine the safety and efficacy of B lymphocyte depletion therapy in patients with refractory childhood-onset systemic lupus erythematosus (SLE).Methods. Seven patients (4 of whom were female), ages 7.7-16.1 years (median 14.8 years) with active SLE that was resistant to standard immunosuppressive agents were treated with B cell depletion. During a 2-week period, patients received two 750-mg/m 2 intravenous infusions of rituximab, with intravenous cyclophosphamide (if they had not previously received this treatment) and high-dose oral corticosteroids.Results. Patients were followed up for a median of 1.0 years, and no serious adverse effects were noted. In all patients, the clinical symptoms and signs for which rituximab therapy was initiated were improved. There was significant improvement in the British Isles Lupus Assessment Group global scores, from a median score of 22 (range 14-37) at baseline to a median score of 6 (range 4-11) at followup (P ‫؍‬ 0.002). In 2 patients with severe multisystem and life-threatening disease unresponsive to standard therapy (including plasma exchange), renal replacement therapy was successfully withdrawn following B cell depletion therapy. These 2 patients have subsequently shown further significant improvement in renal function and proteinuria.Conclusion. This open-label study demonstrates that targeted B cell depletion therapy can be a safe and efficacious addition to therapy with standard immunosuppressive agents in patients with refractory childhood SLE. The drugs used for treatment of childhood SLE need to be the most effective, least toxic agents, allowing normal growth and development.

show abstract

Section: Discussionmentioning

confidence: 99%

B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus

Marks¹,

Patey²,

Brogan³

et al. 2005

Arthritis & Rheumatism

143

View full text Add to dashboard Cite

show abstract

“…It has been shown that anti-DNA antibodies and DNA-anti-DNA antibodies complexes are deposited on many organs, including the kidney, which leads to tissue inflammation [2,3]. The incidence of clinical immune complex-mediated glomerulonephritis in SLE patients range between 30-50% [4][5][6][7]. Different studies suggest a strong correlation between increasing levels of anti-DNA antibodies and subsequent activation of the disease [8,9].…”

Section: Introducctionmentioning

confidence: 99%

DNase1 activity in systemic lupus erythematosus patients with and without nephropathy

et al. 2009

View full text Add to dashboard Cite

“…Çalışmamızda aktiflik ve kroniklik indeksinin istatistiksel olarak prognostik önemi gösterilememiş-tir. Bazı çalışmalarda, hastalığın başlangıcından biyopsi yapılana dek geçen süre (37) , proteinüri miktarı (13) , tedavi süresi (38) ve kompleman düşüklüğü (38,39) renal sonuçlar ile ilişkili bulunmuşken, çalışmamızda bu belirteçler ile istatistiksel olarak anlamlı ilişki saptanmamıştır.…”

Section: Discussionunclassified

“…Çalışmamızda, 5 yıllık renal sağka-lım %85.4, hasta sağkalımı %96.4, mortalite oranı %3.5 olarak bulunmuştur. Sağkalım oranlarımız yapılan diğer pediyatrik çalışmalar (39,45,46) ile benzer hatta birçoğundan daha iyi görünmektedir.…”

Section: Discussionunclassified

Evaluation the effectiveness of intravenous cyclophosphamide treatment in children with lupus nephritis

Al¹,

Emre²,

Bilge³

et al. 2017

Cocuk Dergisi

View full text Add to dashboard Cite

Lupus nephritis in children ? a review of 167 patients

Cited by 67 publications

References 6 publications

B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus

B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus

DNase1 activity in systemic lupus erythematosus patients with and without nephropathy

Evaluation the effectiveness of intravenous cyclophosphamide treatment in children with lupus nephritis

Contact Info

Product

Resources

About